LIVE LONGER
Imagine this: a world where cancer is caught early enough to be effectively treated without the need for debilitating surgery or destructive chemotherapy. A world where we do not have to suffer the loss of loved ones who leave us too early. Thanks to Al’s power and genetic sequencing advances, Renovaro is taking the lead in making this vision a reality by combining advanced diagnostic and personalized immunotherapy.
NEWS
Our Story
Renovaro Inc.
Renovaro is driven by an unwavering commitment to revolutionize healthcare. Our primary objectives encompass pioneering advancements in AI, diagnostics and therapies for patients with cancer.
RenovaroCube
Renovaro Cube is commited to use liquid biopsies for the full patient journey.
RenovaroBio
RenovaroBio has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases.
From Strength to Strength
Both RenovaroCube and RenovaroBio are at the forefront of oncology innovations, revolutionizing the field of cancer treatment. RenovaroBio is committed to a future where survival is increased the toxic effects of chemotherapy are eliminated. They are focused on developing next-generation diagnostics and immunotherapy, specifically dendritic cell-based therapy, as an alternative to chemotherapy.
RenovaroCube is dedicated to develop the next generation of diagnostics for early detection of the disease, treatment selection, response prediction and follow-up of disease spanning the full patient journey using only one simple vial of blood (liquid biopsies). Collectively we offer a holistic approach to cancer treatment, benefiting not only patients but also clinicians and healthcare providers by employing a vertically integrated approach.
Our mission
Integrating the power of AI from diagnosis through treatment and recovery
Our Goals
By fostering global collaborations, we seek to accelerate the translation of scientific breakthroughs into tangible solutions, positively impacting lives worldwide.
Renovaro is dedicated to creating a healthier and more resilient future for humanity through innovation, ethical practices, and a relentless pursuit of excellence in biotechnology.
- To impact patients from diagnostics through theraputic intervention
- A future free from toxic Chemotherapy
- Detection of diseases before the appearance of symptoms
- Non-invasive liquid biopsy testing
Our Team
COMMITTED TO RADICALLY ACCELERATE PRECISION MEDICINE
Maurice van Tilburg – Glimne
Chairman & CEO RenovaroCube
Chairman Maurice van Tilburg has held several senior positions in the Financial Services industry and Tech enterprises combining general management, technology, operational service delivery, financial
David Weinstein
Director & Chief Executive Officer (CEO)
Director & Chief Executive Officer (CEO) Mr. Weinstein has thirty years of experience with U.S. securities and investment banking firms. He has been a Managing
Douglas W. Calder
Director
Director Since 2015, Mr. Calder has served as president and a director of Vycellix, Inc and its subsidiaries and affiliates. He has also served as
Mark Collins, Phd
Director
Director Dr. Collins has dedicated his 40-year career to leveraging computers in drug discovery, blending biology, AI, and software. He has played key roles in
James A. McNulty
Director
Director Mr. McNulty serves as CFO for MIRALOGX, LLC, a privately held incubator which develops and licenses pharmaceutical intellectual property to private and public entities.
Nathen Feuntes
Chief Financial Officer (CFO)
On January 2, 2025, the Company appointed Nathen Fuentes as Chief Financial Officer of the Company. Mr. Fuentes most recently served as Chief Financial Officer